Jakob Dupont, MD, on ATA188’s Potential in All Forms of Multiple Sclerosis
The global head of research and development at Atara Biotherapeutics discussed ATA188 ahead of anticipated data readouts this month.
Epstein-Barr Virus and Autoimmune Disease: Jakob Dupont, MD
The global head of research and development at Atara Biotherapeutics discussed the future of MS research.
Elucidating Associations Between EBV and MS: Jakob Dupont, MD
The global head of research and development at Atara Biotherapeutics discussed the link between EBV and MS.
ATA188, a Cell Therapy for Progressive MS: Jakob Dupont, MD, MA
The head of global research and executive vice president of Atara Biotherapeutics discussed the development of ATA188.
Jakob Dupont, MD: Phase 1 Data on Cell Therapy for Progressive MS
The executive vice president and head of global research and development at Atara Biotherapeutics spoke to the findings of a phase 1 study of the cell therapy ATA188.